Nombre total de pages vues

mardi 31 décembre 2013

Ronning Against Cancer (breast cancer)’s last run on Tuesday,December 31st 2013. Great motivation and Well-Being / Wellness to run !!! Happy New Year’s Eve party!!!

Time : 55’
Distance : 13 km

Great run in the nature with good feelings and wellness J

lundi 30 décembre 2013

Pour bien commencer la nouvelle année 2014, mise en application de la loi votée en 2012 sur la hausse de TVA.

Dès le 1er janvier 2014 :

-         Le taux normal passera  de 19,6% à 20 %
-         Le taux intermédiaire de 7 à 10 %.

Quant au taux réduit, qui devait à l'origine descendre à 5 %, il sera maintenu à 5,5 %. Ces mesures doivent apporter plus de 6 milliards d'euros à l'État, dans le but de financer une partie du crédit d'impôt compétitivité emploi  (CICE) qui allégera le coût du travail des entreprises de 10 milliards l'an prochain. 

Quelles seront sont donc les conséquences pour les ménages et les entreprises ?

dimanche 29 décembre 2013

Latest world cancer statistics - Global cancer burden rises to 14.1 million new cases in 2012: Marked increase in breast cancers must be addressed . Estimated Incidence, Mortality and Prevalence Worldwide in 2012 by International Agency for Research on Cancer (World Health Organization)

International Agency for Research on Cancer
World Health Organization

Lyon/Geneva, 12 December 2013 – The International Agency for Research on Cancer (IARC),
the specialized cancer agency of the World Health Organization, today released the latest data on cancer incidence, mortality, and prevalence worldwide1.The new version of IARC’s online database, GLOBOCAN 2012, provides the most recent estimates for 28 types of cancer in 184 countries worldwide and offers a comprehensive overview of the global cancer burden.

GLOBOCAN 2012 reveals striking patterns of cancer in women and highlights that priority
should be given to cancer prevention and control measures for breast and cervical cancers

Global burden rises to 14.1 million new cases and 8.2 million cancer deaths in 2012
According to GLOBOCAN 2012, an estimated 14.1 million new cancer cases and 8.2 million
cancer-related deaths occurred in 2012, compared with 12.7 million and 7.6 million, respectively, in 2008. Prevalence estimates for 2012 show that there were 32.6 million people (over the age of 15 years) alive who had had a cancer diagnosed in the previous five years.

The most commonly diagnosed cancers worldwide were those of the lung (1.8 million, 13.0% of the total), breast (1.7 million, 11.9%), and colorectum (1.4 million, 9.7%). The most common causes of cancer death were cancers of the lung (1.6 million, 19.4% of the total), liver (0.8 million, 9.1%), and stomach (0.7 million, 8.8%).

Projections based on the GLOBOCAN 2012 estimates predict a substantive increase to
19.3 million new cancer cases per year by 2025, due to growth and ageing of the global
population. More than half of all cancers (56.8%) and cancer deaths (64.9%) in 2012 occurred in less developed regions of the world, and these proportions will increase further by 2025.

Sharp rise in breast cancer worldwide
In 2012, 1.7 million women were diagnosed with breast cancer and there were 6.3 million women alive who had been diagnosed with breast cancer in the previous five years. Since the 2008 estimates, breast cancer incidence has increased by more than 20%, while mortality has increased by 14%. Breast cancer is also the most common cause of cancer death among women (522 000 deaths in 2012) and the most frequently diagnosed cancer among women in 140 of 184 countries worldwide. It now represents one in four of all cancers in women.

“Breast cancer is also a leading cause of cancer death in the less developed countries of the
world. This is partly because a shift in lifestyles is causing an increase in incidence, and partly
because clinical advances to combat the disease are not reaching women living in these regions,” says Dr David Forman, Head of the IARC Section of Cancer Information, the group that compiles the global cancer data.

Generally, worldwide trends show that in developing countries going through rapid societal and economic changes, the shift towards lifestyles typical of industrialized countries leads to a rising burden of cancers associated with reproductive, dietary, and hormonal risk factors.

Incidence has been increasing in most regions of the world, but there are huge inequalities
between rich and poor countries. Incidence rates remain highest in more developed regions, but mortality is relatively much higher in less developed countries due to a lack of early detection and access to treatment facilities. For example, in western Europe, breast cancer incidence has reached more than 90 new cases per 100 000 women annually, compared with 30 per 100 000 in eastern Africa. In contrast, breast cancer mortality rates in these two regions are almost identical, at about 15 per 100 000, which clearly points to a later diagnosis and much poorer survival in eastern Africa.

“An urgent need in cancer control today is to develop effective and affordable approaches to the early detection, diagnosis, and treatment of breast cancer among women living in less developed countries,” explains Dr Christopher Wild, Director of IARC. “It is critical to bring morbidity and mortality in line with progress made in recent years in more developed parts of the world.”

Cervical cancer, an avoidable cause of death among women in sub-Saharan Africa
With 528 000 new cases every year, cervical cancer is the fourth most common cancer affecting women worldwide, after breast, colorectal, and lung cancers; it is most notable in the lower-resource countries of sub-Saharan Africa. It is also the fourth most common cause of cancer death (266 000 deaths in 2012) in women worldwide. Almost 70% of the global burden falls in areas with lower levels of development, and more than one fifth of all new cases are diagnosed in India.

“Cervical cancer can have devastating effects with a very high human, social, and economic cost, affecting women in their prime. But this disease should not be a death sentence, even in poor countries,” explains Dr Rengaswamy Sankaranarayanan, a lead investigator for an IARC research project with a focus on cervical cancer screening in rural India. “Low-tech and inexpensive screening tools exist and could significantly reduce the burden of cervical cancer deaths right now in less developed countries.”

In sub-Saharan Africa, 34.8 new cases of cervical cancer are diagnosed per 100 000 women annually, and 22.5 per 100 000 women die from the disease. These figures compare with 6.6 and 2.5 per 100 000 women, respectively, in North America. The drastic differences can be explained by lack of access to effective screening and to services that facilitate early detection and treatment.

“These findings bring into sharp focus the need to implement the tools already available for cervical cancer, notably HPV vaccination combined with well-organized national programmes for screening and treatment,” stresses Dr Wild.

Note to the Editor
The online GLOBOCAN 2012 resource at is easy to use and has facilities to produce maps and other graphics. In addition, a series of fact sheets describe the overall cancer burden within specific areas or countries. GLOBOCAN 2012 also provides the user with facilities to predict the future cancer incidence and mortality burden over the next 20 years according to projected population ageing and population growth.

These estimates are based on the most recent data available at IARC and on information publicly available on the World Wide Web. GLOBOCAN 2012 provides a global profile of cancer that has been developed using a number of methods that are dependent on the availability and the accuracy of the data. National sources are used where possible, with local data and statistical modelling used in their absence.

Incidence/mortality data:
Ferlay J, Soerjomataram I, Ervik M, Dikshit R, Eser S, Mathers C, Rebelo M, Parkin DM, Forman D, Bray, F (2013). GLOBOCAN 2012 v1.0, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 11 [Internet]. Lyon, France: International Agency for Research on Cancer. Available from
Prevalence data:
Bray F, Ren JS, Masuyer E, Ferlay J (2013). Global estimates of cancer prevalence for 27 sites in the adult population in 2008. Int J Cancer, 132(5):1133–1145. PMID:22752881

For more information, please contact
Véronique Terrasse, Communications Group, or at +33 (0) 645 284 952
or Dr Nicolas Gaudin, IARC Communications

Corrida pédestre Internationale de Houilles 2013 : Du nouveau pour la Corrida de Houilles avec une course populaire et une course élite pour la 42ème édition. dimanche 29 décembre 2013.

Depuis sa création en 1972, la Corrida pédestre internationale de Houilles porte bien son nom. En effet, peu de courses sur route en France, voire même en Europe, peuvent s’enorgueillir d’offrir au public un plateau d’athlètes internationaux d’aussi haut niveau.

La 42e édition de la Corrida pédestre internationale de Houilles se déroulera le dimanche 29 décembre.


Le programme de la journée



Animations musicales des fanfares itinérantes, attractions, feu d'artifice de clôture, donnent à la corrida son caractère festif si particulier.
Dès 14h, le public applaudira les formations suivantes : les  « Batucada et percussion » avec  ses rythmes et instruments brésiliens ; les Belges de « Borains en Banda », le « Cyril Jazz Band », Les « Pour Koa Pas » et leurs étranges instruments. Ambiance garantie ! À noter également la présence des Bikers Harley Davidson.

Clôture de la manifestation

1   8h : feu d'artifice, parc Charles-de-Gaulle.


Course populaire

·         14h45 : départ de la course populaire, place du 14-Juillet.
·         Arrivée : place Michelet.
·         Ouverte à tous, à partir de la catégorie des cadets (nés avant le 1er janvier 1997).
·         Course qualificative pour les championnats de France.
·         Distance : 10 km.


Course des AS

·         16h30 : départ de la course des As, place du 14-Juillet.
·         Arrivée : place Michelet.
·         Ouverte aux licenciés de la Fédération française d'athlétisme ou d'une fédération étrangère. 
·         Course homologuée FFA et qualificative pour les championnats de France.
·         Distance : 10 km.

Pour en savoir plus :

vendredi 27 décembre 2013

AVIS DE RECHERCHE URGENT! Manuella Lambrich, 17 ans, a disparu vendredi 20 décembre 2013 vers 18h à Meaux.

Résultats du Semi Marathon de Vincennes 2013, ce dimanche 27 octobre: dernière course de « Ronning Against Cancer and Ronald Tintin» dans la cadre de l’opération « octobre rose 2013 » pour parler du cancer du sein aux couleurs de l’Institut Curie !!!

Hello très chères lectrice et lecteurs ;)

Dimanche 27 octobre 2013

Paris – bois de Vincennes à 10 : 10

Malgré la pluie et le vent parfois, j’avais décidé de prendre le départ de la course « Semi Marathon de Vincennes » pour la dernière course dans le cadre de l’opération « Octobre Rose 2013 » pour soutenir la lutte contre le cancer du sein aux couleurs de l’Institut Curie !!!

Distance :21,100 km
Temps : 1h22’34’’
Classement : 29ème / 2535

Avec les conditions mauvaises (pluie, vent…) pour courir, j’ai pu profiter pour courir sans penser au chrono avec un certain bien-être dans le paysage bien agréable du bois de Vincennes sous le soleil !!!

Pour en savoir plus sur "Ronning Against Cancer's challenge beyond the limits and don't give up" :

lundi 23 décembre 2013

Ronning Against Cancer (breast cancer)’s weekly training report 12/16/2013- 12/22/2013! Awesome trainning. Go to Paris Marathon 2014…Let’s get rid of breast cancer! Great motivation and Well-Being / Wellness to run !!!

Ronning Against Cancer (breast cancer) ran during the week of December 16th – December 22nd 2013...

Total distance : 41.10 km
Total calories: 2 493
Total time: 3h12
Workouts : 3

Awesome training and great motivation to run...

The weather  is cold, but nice to run with well-being in the nature;-)

Ronning Against Cancer’s last long run before Christmas in 2013 on Sunday, December 22nd 2013. Go to Paris Marathon 2014…Let’s get rid of breast cancer! Great motivation and Well-Being to run !!!

Time : 1h17’
Distance : 17 km

1)      Warm up : 9 km in 48’ 
2)      Tempo run with up and down hill : 15’
3)      Cooldown run : 4 km in 24’

The weather is windy and cold, but nice to run with well-being in the nature;-)

Ronning Against Cancer’s last race in 2013 « Marathon Amical du Bois de Vincennes » to support Institut Curie and breast cancer on Sunday, December 1st 2013. Great motivation and Well-Being

Ronning Against Cancer’s last race in 2013 « Marathon Amical du Bois de Vincennes » to support Institut Curie and breast cancer on Sunday, December 1st 2013. Great motivation and Well-Being!!!

Ranking : 2nd / 11

Ronning Against Cancer 

samedi 21 décembre 2013

Janet D. Rowley, Who Discovered Cancer Can Be Genetic, Dies at 88 – The New York Times on Friday, December 20th 2013 by By MARGALIT FOX

Dr. Janet D. Rowley, a physician who four decades ago became the first person to show a conclusive link between certain genetic abnormalities and certain cancers, died on Tuesday at her home in Chicago. She was 88.

The death, from complications of ovarian cancer, was announced by theUniversity of Chicago, where Dr. Rowley was the Blum-Riese distinguished service professor of medicine, molecular genetics and cell biology, and human genetics.
Dr. Rowley, described by The New York Times in 2011 as “the matriarch of modern cancer genetics,” made her pathbreaking discovery in 1972, when she found that a particular type of leukemia could result when two chromosomes abnormally exchanged genetic material.
Her findings helped establish cancer as a genetic disease. They also made possible the development of targeted drug therapies for specific cancers.
For her work, Dr. Rowley received the Lasker Award, given for distinguished contributions to medical science; the National Medal of Science from President Bill Clinton; and the Presidential Medal of Freedom from President Obama, among many other honors.
Janet Davison was born in New York City on April 5, 1925, and at 2 moved with her family to Chicago. At 15, she entered Hutchins College of the University of Chicago, which let gifted high school students start college.
After receiving her bachelor’s degree at 19, she was accepted to the university’s medical school but was told she would have to wait nine months to enroll: the school had already accepted its quota of women for the year — three in a class of 65.
She earned her M.D. from Chicago in 1948 and that year married a classmate, Dr. Donald Rowley. The mother of four young sons before long, she worked part time at a local clinic for children with Down syndrome.
The prospect of a research career, Dr. Rowley later said, did not occur to her.
“I actually thought I had it made working three days a week,” she said in a 2009 interview. “I could take care of my children, garden, weave and go to museums.”
Then, in 1961, Dr. Rowley joined her husband on a sabbatical year at Oxford University. Because Down syndrome was known to be caused by a chromosomal abnormality, she chose to spend her year there studying new methods of chromosome analysis.
Returning to Chicago, she begged the university for a room, a microscope and sufficient salary to pay a babysitter. The director of the laboratory that offered her space was an authority on leukemia, and Dr. Rowley began hunting for chromosomal anomalies in genetic samples from his patients.
While genetic abnormalities had long been known to cause other diseases, Dr. Rowley would be the first to show that they were also a cause — and not merely a consequence, as had been supposed — of cancer.
Her discovery took 10 years of peering through the microscope: at the time it was hard to tell chromosomes apart, even under magnification.
“This was less than a decade after Watson and Crick’s discovery,” Dr. Rowley told The Times in 2011, referring to James D. Watson and Francis Crick, the biologists who discovered the structure of DNA in 1953. “We were only beginning to have a notion of what DNA was like. There weren’t the right tools yet to stain it, cut it apart, examine and manipulate it.”
Dr. Rowley’s first significant advance came in 1970, on another sabbatical at Oxford. There she was introduced to a chemical staining technique, newly developed in Sweden, that made chromosomes appear striated and, as a result, easier to differentiate.
She stained and studied an array of chromosomes from patients with blood cancers, photographing the resulting images. Back in Chicago, she cut the photos into tiny fragments, with each fragment showing a chromosome in isolation — “paper dolls,” her children called them.
One day in 1972, Dr. Rowley cut up a sheaf of photos from a patient with acute myeloid leukemia, known as A.M.L. She laid the fragments out, chromosome by chromosome, on her dining table and ordered the children not to sneeze.
Aligned, the photos told a story of mutation. As Dr. Rowley noticed, two chromosomes had inappropriately swapped genetic material: a piece of chromosome 8 was now on chromosome 21, and vice versa. Examining photos from other A.M.L. patients, she saw that nearly every set showed the identical genetic swap.
Surely, she thought, other researchers had observed this before. She rushed to the library.
“They hadn’t,” Dr. Rowley told The Associated Press in 1988. “It was one of the greatest moments of my life.”
She soon identified another swap, between chromosomes 9 and 22, which resulted inchronic myelogenous leukemia, or C.M.L.
It was then so unorthodox to regard cancer as a genetic disease that “I got sort of amused tolerance at the beginning,” Dr. Rowley later said.
In 1977, she and her colleagues uncovered a third swap — between chromosomes 15 and 17 — which caused acute promyelocytic leukemia.
“That showed what we’d observed with the other two wasn’t an anomaly,” Dr. Rowley told The Times in 2011. “The third finding made me a believer.”
In chromosomes that had undergone the swaps — known in medical parlance as translocations — genes regulating processes like cell growth and cell division were no longer where they ought to be. As a result, cancer could arise.
Over the years, researchers have identified hundreds more translocations linked to specific cancers. The discoveries have given rise to drugs that target the genetic defects underpinning the cancers while sparing healthy cells.
Among the most successful of these drugs is Gleevec, used to treat C.M.L. Before its development, C.M.L. patients typically lived three to five years after diagnosis. Today, 90 percent are considered cured and have a normal life span.
Dr. Rowley’s husband, a noted pathologist at the University of Chicago, died this year; their eldest son, Donald, died in 1983. Survivors include three sons, David, Robert and Roger, and five grandchildren.
Her other awards include the Japan Prize and a lifetime achievement award from the American Association for Cancer Research. From 2002 to 2009, she served on President George W. Bush’s Council on Bioethics.
Despite her laurels, Dr. Rowley by all accounts remained almost preternaturally modest.
“People accuse me of being too humble,” she told The Times in 2011. “But looking down a microscope at banded chromosomes is not rocket science.”

1) Warm up run : 4 km in 20 minutes.

2) Tempo running :
2000 m:7’20’’
2000 m:7’14’’
1200 m:4’18’’
400 m:1’08’’

3) Cooldown run : 2 km in 12 minutes.

The weather is cold, but really nice to run with well-being ;-)

samedi 14 décembre 2013

Objectif Marathon de Paris 2014 - Début de l’aventure du dépassement de soi "Ronning Against Cancer"au-delà des limites : Reprise doucement de l’entraînement par temps froid, à l’approche Noël

Mercredi 11 décembre 2013,

Il fait froid et nuit, mais le plaisir de reprendre le running doucement était au RDV avec la motivation.

1) Footing d’échauffement de 6 km en 32 minutes.

2) Séance de VMA courte 7 × 450 (1’20’’)

3) Footing de récupération de 3 km en 19 minutes.

Froid (3°C) au début, mais trop chaud à la fin !!! ;-)